The sequence of disease|modifying therapies in relapsing multiple ...

The sequence of disease-modifying therapies in relapsing multiple ...

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded considerably over the last 10 years with the approval of multiple new ...

The sequence of disease-modifying therapies in relapsing multiple ...

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded considerably over the last 10 years with the approval ...

The sequence of disease-modifying therapies in relapsing multiple ...

involved in treating people with RMS throughout the entire course of their disease. Keywords Multiple sclerosis · Therapeutic drug monitoring · Selection for ...

Sequencing of high-efficacy disease-modifying therapies in multiple ...

The reversibility of immune system effects should be a key consideration for DMT sequence selection. This feature varies across DMTs and should factor more ...

[PDF] The sequence of disease-modifying therapies in relapsing ...

This review is intended to help neurologists make informed decisions when treating RMS by summarizing the known data for each DMT and raising awareness of ...

Disease-modifying therapies for adults with multiple sclerosis ...

Since 1993, DMTs have been approved in the United States for treating relapsing forms of MS; most of these therapies are approved for use in other countries.

Disease modifying therapy switching in relapsing multiple sclerosis

The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms.

Treatment switches of disease-modifying therapies in people with ...

Commonly used MS classifications try to account for a variable presentation from disease onset and during the disease course [relapsing- ...

Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness ...

the use of disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis (RRMS and PPMS, respectively). Following ...

Sequencing of disease-modifying therapies for relapsing–remitting ...

The chronic nature of the disease and the multiple treatment options make benefit–risk-based sequencing of therapy essential to ensure optimal care. The ...

Evolution of Disease Modifying Therapy Benefits and Risks - Frontiers

BackgroundStrategies for sequencing disease modifying therapies (DMTs) in multiple ... relapsing multiple sclerosis: a post hoc analysis of the CLARITY study.

Personalized Use of Disease-Modifying Therapies in Multiple ...

DMTs aim to reduce clinical relapse frequency, slow the accumulation of neurological disabilities, and prevent the development of SPMS in relapsing MS patients, ...

Correction to: The sequence of disease-modifying therapies in ...

Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations · Correction to ...

Utilisation of disease modifying treatment and diversity of treatment ...

To evaluate utilisation and treatment patterns of disease modifying treatments (DMTs) for relapsing remitting multiple sclerosis (RRMS).

Multiple Sclerosis Therapy Consensus Group (MSTCG)

However, there may be cases with persistent and documented paraclinical disease activity in which immunotherapies may be indicated in the ...

Comparison of ofatumumab and other disease-modifying therapies ...

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & ...

The sequence of disease-modifying therapies in relapsing multiple ...

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.-article.

The sequence of disease-modifying therapies in relapsing multiple ...

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations · List of references.

Disease modifying treatment guidelines for multiple sclerosis in the ...

Relapsing MS not on treatment and yet do not show evidence of new disease activity (no relapses, MRI changes or progression ) for > 1 year or disease activity ...

Sequencing of high-efficacy disease-modifying therapies in multiple ...

The landscape of existing therapies with an eye to the future when planning for optimal DMT sequencing is discussed, ...